ECPV most commonly refers to one of two things in medicine: Equus caballus papillomavirus (EcPV), a family of viruses that infect horses and can cause skin tumors and cancers, or extracorporeal photopheresis (ECP), a blood treatment used for certain cancers and immune disorders. Which one you’re looking for depends on whether you’re in a veterinary or human medical context. Here’s what you need to know about both.
Equine Papillomavirus (EcPV)
Equus caballus papillomavirus, abbreviated EcPV, is a group of small DNA viruses that specifically infect horses. At least eight types have been identified (EcPV1 through EcPV8, with EcPV9 recently detected), each associated with different kinds of skin and mucosal lesions. These viruses target keratinocytes, the cells that make up the outer layers of skin and mucous membranes. Infection typically requires some form of skin damage, even tiny micro-wounds, to let the virus reach deeper cell layers.
EcPV2 is the most clinically significant type. It has been found in penile, vulvar, clitoral, and oral papillomas (wart-like growths), as well as in squamous cell carcinomas, a type of skin cancer. The link between EcPV2 and genital cancers in horses is now widely accepted, similar to how certain human papillomaviruses cause cervical cancer in people. EcPV8 is also notable, appearing in viral plaques, papillomas, and squamous cell carcinomas. Other types (EcPV1, 3 through 7) tend to cause milder conditions like ear plaques and genital plaques.
Transmission and Risk Factors
Research suggests that EcPV infection in horses without symptoms is more common than previously thought. Studies in western Canada found widespread evidence of EcPV2 in apparently healthy horses. Sexual transmission appears to be one route: EcPV9 was first discovered in the semen of a stallion with a penile lesion. Thoroughbreds may face higher infection risk, possibly due to genetic susceptibility or breeding practices that increase transmission opportunities. Horses of any breed can carry the virus without visible lesions, making it difficult to track the spread through a population.
Extracorporeal Photopheresis (ECP)
In human medicine, ECP (sometimes written as ECPV in shorthand) is a procedure that treats certain immune-related conditions by modifying a patient’s own white blood cells outside the body and then returning them. The FDA approved it in 1988 for Sézary syndrome, a form of cutaneous T-cell lymphoma (CTCL), which is a cancer of immune cells that primarily affects the skin.
How the Procedure Works
During ECP, blood is drawn from the patient and separated into its components. The white blood cell layer is isolated and mixed with a light-sensitizing compound called 8-methoxypsoralen, then exposed to ultraviolet A (UVA) light. This combination alters the white blood cells in ways that retrain the immune system once the treated cells are returned to the bloodstream.
Scientists originally believed the treatment worked simply by killing off harmful immune cells. The current understanding is more nuanced. When the treated cells are reinfused, they trigger a chain of immune responses: the body produces specialized immune cells called dendritic cells, the balance of inflammatory signals in the blood shifts, and a population of regulatory T-cells expands. These regulatory cells act as peacekeepers, calming overactive immune responses. This is why ECP works for conditions where the immune system is either attacking the body’s own tissues or rejecting a transplanted organ.
Conditions Treated With ECP
Cutaneous T-cell lymphoma remains the primary use, particularly the erythrodermic form where cancer cells cause widespread skin redness and scaling. Beyond cancer, ECP has expanded into transplant medicine and autoimmune diseases. The American Society for Apheresis recognizes it for a range of conditions:
- Graft-versus-host disease (GVHD): Both acute and chronic forms, where donated bone marrow cells attack the recipient’s body after a stem cell transplant.
- Organ transplant rejection: Cardiac transplant rejection (both prevention and treatment), lung transplant complications like bronchiolitis obliterans syndrome, and liver transplant rejection.
- Skin conditions: Severe pemphigus vulgaris (a blistering skin disease), disseminated pustular psoriasis, and atopic dermatitis.
- Autoimmune diseases: Scleroderma, which causes hardening of the skin and connective tissues. Earlier clinical applications also included lupus and rheumatoid arthritis.
Response Rates for GVHD
ECP has become an important option for patients whose graft-versus-host disease doesn’t respond to steroids. A large meta-analysis covering over 1,000 patients found an overall response rate of 72% for steroid-resistant acute GVHD. The results varied significantly by organ: skin symptoms responded best at 89%, gastrointestinal involvement responded at 54%, and liver GVHD had the lowest response at 36%. Chronic GVHD was first treated with ECP in 1994 and has since become one of the procedure’s most common uses.
How to Tell Which One Applies to You
If you encountered “EcPV” in a veterinary context, particularly related to horses with skin growths, warts, or genital lesions, you’re dealing with equine papillomavirus. If you saw “ECP” or “ECPV” in connection with a human blood treatment, cancer therapy, or transplant care, it refers to extracorporeal photopheresis. The abbreviations are easy to confuse, but the two have nothing in common beyond sharing a few letters.